Scroll to top
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Skip to content
About
Company
About CLINUVEL
Risk Management & ESG Statement
Mission, Vision & Values
History & Future
People
Board
Management
Corporate Governance
Pharmaceutical Technology
SCENESSE®
About Melanocortins
Published Research
Scientific Communiqués
Pipeline
Disease Entities
Erythropoietic Protoporphyria (EPP)
Variegate Porphyria (VP)
Vitiligo
DNA Repair
Xeroderma Pigmentosum (XP)
Arterial Ischaemic Stroke (AIS)
Healthcare Solutions
Investors
News
Latest News
Share Price
Announcements Calendar
CLINUVEL Online
ASX Announcements
Company Snapshot
Financial Overview
Shareholder Information
Media Coverage
Analyst Coverage
Annual Reports
Enquiries
FAQ
© CLINUVEL PHARMACEUTICALS LTD 2022. All rights reserved. |
Sitemap
|
Disclaimer
|
Privacy Policy
To report
suspected adverse reactions
, contact CLINUVEL via
safety@clinuvel.com
or (US only) the FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Follow Us
–
Fb.
Tw.
Li.
Yt.
Inst.
Contact Us
Search for
Back
2020 Announcements
Corporate
Presentation
1 min read
Jefferies Virtual London Healthcare Conference Presentation
Author
CLINUVEL
Published
November 20, 2020
Home
News
Archive
2020 Announcements
Jefferies Virtual London Healthcare Conference Presentation
20 November 2020
Download presentation & speaker's notes
Recent Posts
Posted by
CLINUVEL
January 27, 2023
2023 Announcements
Corporate
Regulatory
6 min read
Technical Note: Developing a melanocortin pipeline
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
Posted by
CLINUVEL
January 23, 2023
2023 Announcements
Corporate
Regulatory
15 min read
NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More